biostudies-literatureLevin MJU.S. Department of Health and Human ServicesU.S. Department of DefenseAstraZeneca2188-2200https://www.ebi.ac.uk/biostudies/studies/S-EPMC9069994biostudies-literatureUnknown386(23)<h4>Background</h4>The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.<h4>Methods</h4>In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one contaiThe New England journal of medicineIntramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.PMC9069994W911QY-21-9-0001Pham DPsachoulia KLaurichesse HWright NConnaire JAlappan RLevinson DJMoka CRampling TBahrami GArends RHBertholon FMartinot JBDe Wit SVila MIgnacio Garcia JMRicamara MAleman FPatel NRamanath VMartin EBuntinx EEssink BJOnder RGuillier AWijewardane PVallejo CBiles DYuan YMcMillan CNear KANewton LDeWeese RJMontgomery RLMenendez-Perez IBeavon RNaguib SGStreicher KEstrada Perez VOchoa Castillo MDRawlins TBello VQuintanilla YCrihfield LCano BMMigaud MCDonlin NPROVENT Study GroupAmin FParikh RPadilla KWDiMarco HOwens MVercammen IThomas RChateloin LElrezzi ERaissi SBurgos JTorres DHaamid SAlozie OSantiago EHoulihan CBardou MKelly EJSardou-Rabia DHopper WFHamal SVera EZapata JFGray RCordero MHafeez HCano Zaldivar MAdams KPangalos MNReilly SManjunathappa AGWilson DBaker HYim YTNEchave-Sustaeta JMDe Langhe JCruz Jentoft ALuu MNunez MBhat JComeche Casanova LSnoeck CGuimard TJacob RSo NLynn RDeplanque DHernandez GBetts JYousef JHowie ECaille-Fenerol CAllavena CRamjee MMendoza GBarus RBotelho-Nevers ELevin MJCano MVKeast SBarnes LUriel ARuch CFalcone LBall DEsser MTFernandes JTan EKoh GCKWLaunay OVishnepolsky MArora SLlerena SAnagua Melendres JDunn LMolina JMRaffi FAldea MLibri VLecompte ASSeegobin SFroget RLewis ARoss DLDevilliers HEtcheverry FWhittley SChaudhry AUstianowski AGarbes Pde Maeyer MZeig SRiggs SEllery ASharbaugh ARalph RSullivan GDey KAlexander LIsmail CNava JDel Nozal JMLee YCSomers SSathyan SAkharia OTempleton AAvila MGonzalez Cediel PSiu BAlcaide FBaron MSmith DBolster EAnderson ACapiau LNdikum JKordsmeier JBrickel HAnagua OBuntinx LBollen HCasanova LTJimenez ESmith TDao MAmbery PMarine MKumar JFrome ALongley NCano GMeulemeester MfalseIntramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.<h4>Background</h4>The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown to have prophylactic and therapeutic effects in animal models. Pharmacokinetic data in humans indicate that AZD7442 has an extended half-life of approximately 90 days.<h4>Methods</h4>In an ongoing phase 3 trial, we enrolled adults (≥18 years of age) who had an increased risk of an inadequate response to vaccination against coronavirus disease 2019 (Covid-19), an increased risk of exposure to SARS-CoV-2, or both. Participants were randomly assigned in a 2:1 ratio to receive a single dose (two consecutive intramuscular injections, one contai2022-01-01T00:00:00Z2022 Jun2026-05-31T12:59:15.733Z2025-04-06T21:50:09.871ZS-EPMC90699943544310610.1056/NEJMoa2116620